Literature DB >> 24677539

Runx1 and Cbfβ regulate the development of Flt3+ dendritic cell progenitors and restrict myeloproliferative disorder.

Ansuman T Satpathy1, Carlos G Briseño, Xiongwei Cai, Drew G Michael, Chun Chou, Sunnie Hsiung, Deepta Bhattacharya, Nancy A Speck, Takeshi Egawa.   

Abstract

Runx1 and Cbfβ are critical for the establishment of definitive hematopoiesis and are implicated in leukemic transformation. Despite the absolute requirements for these factors in the development of hematopoietic stem cells and lymphocytes, their roles in the development of bone marrow progenitor subsets have not been defined. Here, we demonstrate that Cbfβ is essential for the development of Flt3(+) macrophage-dendritic cell (DC) progenitors in the bone marrow and all DC subsets in the periphery. Besides the loss of DC progenitors, pan-hematopoietic Cbfb-deficient mice also lack CD105(+) erythroid progenitors, leading to severe anemia at 3 to 4 months of age. Instead, Cbfb deficiency results in aberrant progenitor differentiation toward granulocyte-macrophage progenitors (GMPs), resulting in a myeloproliferative phenotype with accumulation of GMPs in the periphery and cellular infiltration of the liver. Expression of the transcription factor Irf8 is severely reduced in Cbfb-deficient progenitors, and overexpression of Irf8 restors DC differentiation. These results demonstrate that Runx proteins and Cbfβ restrict granulocyte lineage commitment to facilitate multilineage hematopoietic differentiation and thus identify their novel tumor suppressor function in myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24677539      PMCID: PMC4014839          DOI: 10.1182/blood-2013-11-539643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Plat-E: an efficient and stable system for transient packaging of retroviruses.

Authors:  S Morita; T Kojima; T Kitamura
Journal:  Gene Ther       Date:  2000-06       Impact factor: 5.250

2.  Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis.

Authors:  Eilon Woolf; Cuiying Xiao; Ofer Fainaru; Joseph Lotem; Dalia Rosen; Varda Negreanu; Yael Bernstein; Dalia Goldenberg; Ori Brenner; Gideon Berke; Ditsa Levanon; Yoram Groner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-09       Impact factor: 11.205

3.  Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow.

Authors:  O W Rokhlin; M B Cohen; H Kubagawa; M Letarte; M D Cooper
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

4.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

5.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

6.  Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow.

Authors:  H J Bühring; C A Müller; M Letarte; A Gougos; A Saalmüller; A J van Agthoven; F W Busch
Journal:  Leukemia       Date:  1991-10       Impact factor: 11.528

7.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

Authors:  K Inaba; M Inaba; N Romani; H Aya; M Deguchi; S Ikehara; S Muramatsu; R M Steinman
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

8.  Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo.

Authors:  Holger Karsunky; Miriam Merad; Antonio Cozzio; Irving L Weissman; Markus G Manz
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

9.  Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells.

Authors:  Catherine M Sawai; Vanja Sisirak; Hiyaa S Ghosh; Esther Z Hou; Michele Ceribelli; Louis M Staudt; Boris Reizis
Journal:  J Exp Med       Date:  2013-10-07       Impact factor: 14.307

10.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre.

Authors:  Jasper de Boer; Adam Williams; George Skavdis; Nicola Harker; Mark Coles; Mauro Tolaini; Trisha Norton; Keith Williams; Kathleen Roderick; Alexandre J Potocnik; Dimitris Kioussis
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

View more
  25 in total

Review 1.  The RUNX complex: reaching beyond haematopoiesis into immunity.

Authors:  Dominic Chih-Cheng Voon; Yit Teng Hor; Yoshiaki Ito
Journal:  Immunology       Date:  2015-10-25       Impact factor: 7.397

2.  IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation.

Authors:  Amy V Paschall; Ruihua Zhang; Chen-Feng Qi; Kankana Bardhan; Liang Peng; Geming Lu; Jianjun Yang; Miriam Merad; Tracy McGaha; Gang Zhou; Andrew Mellor; Scott I Abrams; Herbert C Morse; Keiko Ozato; Huabao Xiong; Kebin Liu
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

3.  Epigenetic control of early dendritic cell lineage specification by the transcription factor IRF8 in mice.

Authors:  Daisuke Kurotaki; Wataru Kawase; Haruka Sasaki; Jun Nakabayashi; Akira Nishiyama; Herbert C Morse; Keiko Ozato; Yutaka Suzuki; Tomohiko Tamura
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

4.  A RUNX-CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes.

Authors:  Koichi Murakami; Haruka Sasaki; Akira Nishiyama; Daisuke Kurotaki; Wataru Kawase; Tatsuma Ban; Jun Nakabayashi; Satoko Kanzaki; Yoichi Sekita; Hideaki Nakajima; Keiko Ozato; Tohru Kimura; Tomohiko Tamura
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

Review 5.  Mouse models for core binding factor leukemia.

Authors:  D W L Chin; N Watanabe-Okochi; C Q Wang; V Tergaonkar; M Osato
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

6.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Authors:  Iléana Antony-Debré; Vladimir T Manchev; Nathalie Balayn; Dominique Bluteau; Cécile Tomowiak; Céline Legrand; Thierry Langlois; Olivia Bawa; Lucie Tosca; Gérard Tachdjian; Bruno Leheup; Najet Debili; Isabelle Plo; Jason A Mills; Deborah L French; Mitchell J Weiss; Eric Solary; Remi Favier; William Vainchenker; Hana Raslova
Journal:  Blood       Date:  2014-12-09       Impact factor: 22.113

Review 7.  Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.

Authors:  Taylor T Chrisikos; Yifan Zhou; Natalie Slone; Rachel Babcock; Stephanie S Watowich; Haiyan S Li
Journal:  Mol Immunol       Date:  2018-03-15       Impact factor: 4.407

8.  CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice.

Authors:  Qi Cai; Robin Jeannet; Wei-Kai Hua; Guerry J Cook; Bin Zhang; Jing Qi; Hongjun Liu; Ling Li; Ching-Cheng Chen; Guido Marcucci; Ya-Huei Kuo
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

9.  Murine myeloproliferative disorder as a consequence of impaired collaboration between dendritic cells and CD4 T cells.

Authors:  Stéphanie Humblet-Baron; John S Barber; Carlos P Roca; Aurelie Lenaerts; Pandelakis A Koni; Adrian Liston
Journal:  Blood       Date:  2018-10-17       Impact factor: 22.113

Review 10.  Transcriptional Control of Dendritic Cell Development.

Authors:  Theresa L Murphy; Gary E Grajales-Reyes; Xiaodi Wu; Roxane Tussiwand; Carlos G Briseño; Arifumi Iwata; Nicole M Kretzer; Vivek Durai; Kenneth M Murphy
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.